CN107530322B - 斑螯素和生物活性斑螯素衍生物的商业上可行的合成 - Google Patents

斑螯素和生物活性斑螯素衍生物的商业上可行的合成 Download PDF

Info

Publication number
CN107530322B
CN107530322B CN201580076312.3A CN201580076312A CN107530322B CN 107530322 B CN107530322 B CN 107530322B CN 201580076312 A CN201580076312 A CN 201580076312A CN 107530322 B CN107530322 B CN 107530322B
Authority
CN
China
Prior art keywords
compound
reaction
formula
bis
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580076312.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN107530322A (zh
Inventor
M.戴维森
S.R.肖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verrica Pharmaceuticals Inc
Original Assignee
Verrica Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56127857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107530322(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Verrica Pharmaceuticals Inc filed Critical Verrica Pharmaceuticals Inc
Priority to CN202111209225.4A priority Critical patent/CN114106013A/zh
Publication of CN107530322A publication Critical patent/CN107530322A/zh
Application granted granted Critical
Publication of CN107530322B publication Critical patent/CN107530322B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D497/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CN201580076312.3A 2014-12-17 2015-12-17 斑螯素和生物活性斑螯素衍生物的商业上可行的合成 Active CN107530322B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111209225.4A CN114106013A (zh) 2014-12-17 2015-12-17 斑螯素和生物活性斑螯素衍生物的商业上可行的合成

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462093396P 2014-12-17 2014-12-17
US62/093,396 2014-12-17
PCT/US2015/066487 WO2016100732A2 (en) 2014-12-17 2015-12-17 Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111209225.4A Division CN114106013A (zh) 2014-12-17 2015-12-17 斑螯素和生物活性斑螯素衍生物的商业上可行的合成

Publications (2)

Publication Number Publication Date
CN107530322A CN107530322A (zh) 2018-01-02
CN107530322B true CN107530322B (zh) 2021-10-15

Family

ID=56127857

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580076312.3A Active CN107530322B (zh) 2014-12-17 2015-12-17 斑螯素和生物活性斑螯素衍生物的商业上可行的合成
CN202111209225.4A Pending CN114106013A (zh) 2014-12-17 2015-12-17 斑螯素和生物活性斑螯素衍生物的商业上可行的合成

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111209225.4A Pending CN114106013A (zh) 2014-12-17 2015-12-17 斑螯素和生物活性斑螯素衍生物的商业上可行的合成

Country Status (12)

Country Link
US (2) US10745413B2 (enExample)
EP (1) EP3233865A4 (enExample)
JP (3) JP6810693B2 (enExample)
KR (1) KR102528106B1 (enExample)
CN (2) CN107530322B (enExample)
AU (2) AU2015364524A1 (enExample)
BR (1) BR112017013029B1 (enExample)
CA (1) CA2971279C (enExample)
HK (1) HK1246276A1 (enExample)
IL (2) IL252907B2 (enExample)
MX (2) MX385473B (enExample)
WO (1) WO2016100732A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6668240B2 (ja) 2013-08-21 2020-03-18 ヴェリカ ファーマシューティカルズ, インコーポレイテッドVerrica Pharmaceuticals, Inc. 皮膚障害の処置のための組成物、方法、およびシステム
AU2015364524A1 (en) 2014-12-17 2017-07-13 Verrica Pharmaceuticals, Inc. Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives
HK1247663A1 (zh) 2015-01-20 2018-09-28 Verrica Pharmaceuticals, Inc. 药用级斑蝥素的定量和制备
CN106674248B (zh) * 2016-12-17 2019-02-26 重庆市中药研究院 一种斑蝥素的合成工艺
CN111278414A (zh) 2017-06-06 2020-06-12 维里卡制药有限公司 皮肤病的治疗
USD900312S1 (en) 2017-06-15 2020-10-27 Verrica Pharmaceuticals, Inc. Applicator
WO2018232277A1 (en) 2017-06-15 2018-12-20 Verrica Pharmaceuticals, Inc. Devices and methods for the treatment of body surface disorders
CN118084861A (zh) 2017-10-04 2024-05-28 维里卡制药有限公司 斑蝥素的合成
WO2019086922A1 (en) * 2017-10-31 2019-05-09 Université de Bourgogne Therapeutical compositions for use in the treatment of non- malignant conditions associated with phosphatidylinositol-3- kinase activation: overgrowth spectrum, cutaneous capillary malformations and seborrheic keratoses
CN113455515A (zh) * 2021-06-24 2021-10-01 广东省农业科学院果树研究所 斑蝥素在制备防治柑橘采后绿霉菌的农药杀菌剂的应用
KR20240012182A (ko) 2022-07-20 2024-01-29 고려대학교 산학협력단 칸타리딘을 유효성분으로 포함하는 교모세포종 예방 또는 치료용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4298752A (en) * 1980-09-19 1981-11-03 Regents Of The University Of California Cycloadduct precursors of cantharidin and method

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4739621Y1 (enExample) 1968-04-18 1972-11-30
US4148893A (en) 1977-06-13 1979-04-10 The Procter & Gamble Company Dermatological compositions
US4895727A (en) 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
JP3117502B2 (ja) 1991-08-27 2000-12-18 株式会社資生堂 皮膚外用剤
JPH05255367A (ja) * 1992-02-28 1993-10-05 Jitsuei O カンタリジン誘導体組成物の製造法及びそれを含む抗ウイルス剤
US5445462A (en) 1993-08-03 1995-08-29 Medi-Flex Hospital Products, Inc. Liquid applicator
WO1995005156A1 (en) 1993-08-17 1995-02-23 Schering-Plough Healthcare Products, Inc. Compositions for treating corns, calluses and warts
US5590780A (en) 1995-06-22 1997-01-07 Wheaton Holding, Inc. Unit dose assembly
FR2754175B1 (fr) 1996-10-07 1999-07-02 Oreal Utilisation d'un organopolysiloxane de nature elastomerique associe a une phase organique dans un produit de demaquillage des ongles
US6030633A (en) 1998-05-18 2000-02-29 West Agro, Inc. Film-forming compositions for protecting animal skin
JPH11335303A (ja) 1998-05-26 1999-12-07 Lion Corp 苦味増強方法及び皮膚外用剤
US6337076B1 (en) 1999-11-17 2002-01-08 Sg Licensing Corporation Method and composition for the treatment of scars
US20030072814A1 (en) 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts
ATE390921T1 (de) * 2001-05-31 2008-04-15 Univ Hong Kong Chinese Zusammensetzung mit demethylcantharidin in kombination mit platinhaltigen antikrebsmitteln und ihre verwendung
US6899897B2 (en) 2001-06-18 2005-05-31 Jaleva, Inc. Gum resin as a carrier for topical application of pharmacologically active agents
US6673031B2 (en) 2001-09-25 2004-01-06 Phillip Mark Liquid applicator
RU2321593C9 (ru) * 2001-10-19 2008-06-20 Изотехника Инк. Синтез аналогов циклоспорина
JP2004059446A (ja) * 2002-07-25 2004-02-26 Mitsui Chemicals Inc 脂環式化合物及びその製造方法
WO2004093786A2 (en) 2003-04-16 2004-11-04 Corium International Covalent and non-covalent crosslinking of hydrophilic polymers and adhesive compositions prepared therewith
US20050019418A1 (en) 2003-07-23 2005-01-27 Crutchfield Charles E. Wart treatment
US20070111954A1 (en) 2003-07-23 2007-05-17 Cuticeuticals, Inc. Apparatus and method of wart treatment
JP2005187330A (ja) 2003-12-24 2005-07-14 Lion Corp 歯牙貼布用製品及びゲル組成物の選定方法
FR2865360B1 (fr) 2004-01-22 2006-05-26 Oreal Applicateur comportant un element d'application solidaire, lors de l'utilisation, d'un recipient contenant un produit a appliquer
FR2872704B1 (fr) * 2004-07-12 2007-11-02 Laurent Schwartz Pluritherapie contre le cancer
US20060110415A1 (en) 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
US20050111900A1 (en) 2004-11-30 2005-05-26 Francesca Fazzolari Ampoule and method of use
FR2885779B1 (fr) 2005-05-23 2007-08-10 Oreal Dispositif de conditionnement et d'application d'un produit cosmetique ou dermatologique
US20070187437A1 (en) 2006-02-10 2007-08-16 Nordson Corporation Dispensing tip for liquid dispensing systems and method of making the same
JP5132071B2 (ja) 2006-03-31 2013-01-30 小林製薬株式会社 皮膚外用剤
DE102006034272A1 (de) 2006-07-18 2008-01-24 Aesculap Ag & Co. Kg Flüssigkeitsspender in der Medizin in Form einer Handhabe sowie dessen Verwendung
CN100465176C (zh) 2006-08-18 2009-03-04 芜湖天远科技开发有限责任公司 一种提取斑蝥素的方法
US20080146674A1 (en) 2006-12-15 2008-06-19 Rosenberg E William Use of gentian violet in treatment of atopic dermatitis
US8518076B2 (en) 2007-01-08 2013-08-27 Advanced Medical Solutions (Plymouth) Limited Surgical adhesive applicator
US8262608B2 (en) 2007-01-25 2012-09-11 Hyperbranch Medical Technology, Inc. Applicators for multiple component formulations and the like, and methods of use thereof
CN101036774B (zh) 2007-04-17 2010-12-29 贵州益佰制药股份有限公司 一种复方斑蝥口服制剂的检测方法
CN101108853B (zh) 2007-07-27 2010-05-26 贵州大学 斑蝥素分离纯化方法
CN100577665C (zh) * 2007-08-16 2010-01-06 广东药学院 一种抗肿瘤活性斑蛰素衍生物及其制备方法
DE102007046600A1 (de) 2007-09-27 2009-04-02 Linhardt Metallwarenfabrik Gmbh & Co Kg Verfahren zum Applizieren eines flüssigen, medizinischen Behandlungsmediums auf einen zu behandelden Bereich sowie Medizinprodukt
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
JP5396125B2 (ja) 2009-03-30 2014-01-22 有限会社日本健康科学研究センター 被膜形成型製剤
CA2775089C (en) 2009-10-08 2015-12-08 Msd Consumer Care, Inc. Low ether composition and delivery apparatus
US20120016320A1 (en) 2010-07-13 2012-01-19 Lin Michael T Method and Device for Liquid Delivery
US20120148520A1 (en) 2010-12-10 2012-06-14 Michael Strobel Organic Iodine Complex Durable Barrier With Antimicrobial Preparations
FR2972928B1 (fr) 2011-03-25 2013-11-29 Urgo Lab Composition contenant une cellulose, une huile vegetale et un solvant volatil, ses utilisations comme pansement
CN102146086B (zh) 2011-04-12 2012-03-07 贵州金桥药业有限公司 一种斑蝥酸钠的制备方法
US20120312709A1 (en) 2011-04-12 2012-12-13 Velcera, Inc. Device for storing and dispensing a medicament, and packaging for containing the same
US9486829B2 (en) 2011-06-04 2016-11-08 Optmed, Inc. Applicator
CN102268006B (zh) 2011-06-15 2013-08-14 北京联合大学生物化学工程学院 一种复合酶提取斑蝥素的方法
US8871801B2 (en) 2011-08-01 2014-10-28 Jacob LEVITT Method of treating acquired perforating dermatosis with cantharidin
CN202920809U (zh) 2012-09-27 2013-05-08 合肥诚者成医药科技有限公司 一种治疗尖锐湿疣的软膏
US9463180B2 (en) 2013-03-14 2016-10-11 Quadex Pharmaceuticals, Llc Treatment of molluscum contagiosum
JP6668240B2 (ja) 2013-08-21 2020-03-18 ヴェリカ ファーマシューティカルズ, インコーポレイテッドVerrica Pharmaceuticals, Inc. 皮膚障害の処置のための組成物、方法、およびシステム
CN103923095A (zh) * 2014-04-23 2014-07-16 遵义医学院 一种去甲基斑蝥素酸钙
US9994584B2 (en) 2014-10-15 2018-06-12 Lixte Biotechnology, Inc. Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid
AU2015364524A1 (en) 2014-12-17 2017-07-13 Verrica Pharmaceuticals, Inc. Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives
HK1247663A1 (zh) 2015-01-20 2018-09-28 Verrica Pharmaceuticals, Inc. 药用级斑蝥素的定量和制备

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4298752A (en) * 1980-09-19 1981-11-03 Regents Of The University Of California Cycloadduct precursors of cantharidin and method

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Ausffihrliche Mitteilung erfolgt an anderer Stelle.;schenck;《德国有机化学》;19531015;全文 *
Cycloaddition Approach to the Curing of Polyimides via Precursor Containing Thiophene-S,S-dioxide;Andrew Magyarosy et al;《Heteroatom Chemistry》;20061026;第17卷(第7期);648-652 *
D.Christopher Braddock et al.Stereochemistry of the Catalysed Diels-Alder Reaction between Cyclopentadiene and Dimethyl Monothionofumarate *
Dramatic Rate Accelerations of Diels-Alder Reactions in 5 M Lithium Perchlorate-Diethyl Ether: The Cantharidin Problem Reexamined;Grieco et al;《Journal of the American Chemical Society》;19900501;第112卷(第11期);4595-4596 *
Homogeneous Catalysis.Transition Metal Based Lewis Acid Catalysts;T.K.Hollis et al;《Tetrahedron》;19931026;第49卷(第25期);5415-5430 *
Lithium Trifluoromethanesulfonimide in Acetone or Diethyl Ether;HANDY;《Synlett》;19951230;全文 *
Organic Reactions at High Pressure. The Preparative Scale Synthesis of Cantharidin;W.G.Dauben et al;《the Journal of Organic Chemistry》;19850423;第50卷(第14期);2576-2578 *
Soft versus Hard Lewis Acids.《Chemical Communication》.1993,1244-1246. *
W.G.Dauben et al.Organic Reactions at High Pressure. The Preparative Scale Synthesis of Cantharidin.《the Journal of Organic Chemistry》.1985,第50卷(第14期),2576-2578. *

Also Published As

Publication number Publication date
BR112017013029B1 (pt) 2022-12-06
KR102528106B1 (ko) 2023-05-03
CN107530322A (zh) 2018-01-02
US20210070771A1 (en) 2021-03-11
MX385473B (es) 2025-03-18
IL252907B2 (en) 2023-08-01
CA2971279C (en) 2023-09-19
US20190002474A1 (en) 2019-01-03
JP6810693B2 (ja) 2021-01-06
US10745413B2 (en) 2020-08-18
MX2021010078A (es) 2021-09-21
AU2015364524A1 (en) 2017-07-13
CN114106013A (zh) 2022-03-01
HK1246276A1 (zh) 2018-09-07
EP3233865A4 (en) 2018-12-05
JP2021073173A (ja) 2021-05-13
JP2024037931A (ja) 2024-03-19
WO2016100732A3 (en) 2016-09-09
BR112017013029A2 (pt) 2018-01-09
IL252907B (en) 2020-06-30
IL274968A (en) 2020-07-30
AU2020244554B2 (en) 2022-10-20
JP2018500336A (ja) 2018-01-11
JP7777726B2 (ja) 2025-12-01
KR20170117027A (ko) 2017-10-20
IL252907A0 (en) 2017-08-31
EP3233865A2 (en) 2017-10-25
CA2971279A1 (en) 2016-06-23
MX2017008097A (es) 2018-01-09
AU2020244554A1 (en) 2020-10-29
WO2016100732A2 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
CN107530322B (zh) 斑螯素和生物活性斑螯素衍生物的商业上可行的合成
Molander Reductions with samarium (II) iodide
Wender et al. Transition Metal-Catalyzed [5+ 2] Cycloadditions of Allenes and Vinylcyclopropanes: First Studies of Endo− Exo Selectivity, Chemoselectivity, Relative Stereochemistry, and Chirality Transfer
US12221452B2 (en) Synthesis of cantharidin
Javadi et al. Oxidation of alkenes and sulfides catalyzed by a new binuclear molybdenum bis-oxazoline complex
Fernandez-Perez et al. Enantiopure bisphosphine ligands with appended crown ether groups as regulation sites for Rh-mediated hydrogenations
Forcher et al. A stereoselective access to a ferrocene-based planar chiral triazolium salt
Guanti et al. Simplified dynemicin analogues: diastereoselective synthesis and evaluation of their activity against plasmid DNA
Wang et al. Enantioselective Michael addition of cyclic ketones to nitroolefins catalyzed by a novel fluorine-insertion organocatalyst
Zhang et al. Methyltrioxorhenium-catalyzed epoxidation of olefins with hydrogen peroxide as an oxidant and pyridine N-oxide ionic liquids as additives
WO2016057606A1 (en) Large-scale diastereoselective syntheses of cycloheptadienylsulfones and stereotetrads
Morten et al. New synthetic strategies for the stereocontrolled synthesis of substituted ‘skipped’diepoxides
Philipova et al. (−)-Fenchone derived epoxy alcohols—preparation and configuration
Marty et al. Diastereoselective synthesis of (1S, 2S, 3R, 6S) 3-chloro-3-methyl-6-isopropenyl-1, 2-cyclohexanediol via Prins reaction induced by Zinc and trimethylsilyl chloride
Shrestha Novel Methodologies to Achieve High Regio-and Site-Selectivity in Complex Molecule Synthesis via Late-Stage Derivatization, Supramolecular-Organocatalyst Interactions, and Nanoparticle-Enabled Functionalization Techniques
Hochstetler Hydroboration of dihydrothujopsene
CN120365177A (zh) 一种以芳基酰胺和叔烷基卤代烷烃为原料的含季碳中心的芳基酰胺类衍生物及其制备方法
Ito Synthetic Utility of Fused-Cyclobutenes: Synthesis of Medium-Sized Cycloalkenes
Lewis et al. The diastereoselective Meth-Cohn epoxidation of camphor-derived vinyl sulfones
Ye Photo-Induced Multifluorinated Arenes C (sp2)-F Functionalization
HK40035593B (en) Synthesis of cantharidin
Chuang Homogeneous catalysis in organic synthesis
Khan Gold-catalysed reactions of alkynyl sulfoxides
Sullivan The total synthesis and manipulations of norcembrenolides
Ye Total Synthesis of Mycolactone E and Iriomoteolide-1b Stereoisomer via Ring-Closing Metathesis Strategies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant